Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

Europe Medical Solution ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.1% 1.1%   Bankruptcy risk   11.5% 12.9% 10.1% 7.7% 6.2% 7.7% 11.0% 11.0%   Credit score (0-100)   22 19 24 30 37 30 22 22   Credit rating   BB BB BB BB BBB BB BB BB   Credit limit (kDKK)   -0.0 -0.0 -0.0 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   -11.2 -98.1 169 272 488 642 0.0 0.0   EBITDA   -11.2 -98.1 169 272 488 642 0.0 0.0   EBIT   -11.2 -98.1 169 272 488 642 0.0 0.0   Pre-tax profit (PTP)   -38.3 -105.3 157.4 267.8 479.4 641.6 0.0 0.0   Net earnings   -38.3 -105.3 157.4 267.8 380.0 500.4 0.0 0.0   Pre-tax profit without non-rec. items   -38.3 -105 157 268 479 642 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   -309 -415 -257 10.4 390 891 841 841   Interest-bearing liabilities   5.1 947 1,014 536 371 0.0 0.0 0.0   Balance sheet total (assets)   535 547 829 613 1,002 1,052 841 841   Net Debt   -523 411 998 478 208 -159 -841 -841     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   -11.2 -98.1 169 272 488 642 0.0 0.0   Gross profit growth   92.0% -779.7% 0.0% 60.4% 79.7% 31.4% -100.0% 0.0%   Employees   0 1 1 1 1 1 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   535 547 829 613 1,002 1,052 841 841   Balance sheet change%   170.3% 2.3% 51.5% -26.1% 63.4% 5.0% -20.0% 0.0%   Added value   -11.2 -98.1 169.4 271.8 488.3 641.7 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -3.0 -4.0 1.0 2.0 3.0 4.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   -1.7% -9.6% 18.6% 33.5% 60.5% 62.5% 0.0% 0.0%   ROI %   -145.4% -18.3% 19.4% 36.5% 74.7% 77.7% 0.0% 0.0%   ROE %   -10.5% -19.5% 22.9% 63.8% 189.6% 78.1% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   -36.6% -43.1% -23.7% 1.7% 39.0% 84.7% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   4,688.8% -418.7% 589.2% 176.0% 42.7% -24.8% 0.0% 0.0%   Gearing %   -1.7% -228.3% -393.9% 5,147.8% 95.0% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   354.2% 3.9% 3.3% 2.2% 2.0% 0.1% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   0.6 0.6 0.8 1.0 1.6 6.5 0.0 0.0   Current Ratio   0.6 0.6 0.8 1.0 1.6 6.5 0.0 0.0   Cash and cash equivalent   528.1 535.9 15.9 57.4 162.5 159.2 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   -309.4 -414.7 -257.4 10.4 390.4 890.9 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 -98 169 272 488 642 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 -98 169 272 488 642 0 0   EBIT / employee   0 -98 169 272 488 642 0 0   Net earnings / employee   0 -105 157 268 380 500 0 0